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The matter of immunology often conjures 
images of the minute: tiny cells on guard 
against tiny invaders. Many immunolo-
gists, not unreasonably, think in micro-
scopic terms—molecular events in disease 
and resistance. Alan Aderem has likewise 
studied the infinitesimal. His early work 
dissected the molecular 
signaling pathways that are 
activated within macro-
phages when these white 
blood cells sense bacterial 
intruders (1, 2).
Later, Aderem’s view 
expanded somewhat. He 
studied the events that 
lead macrophages to en-
gulf pathogens (3). He 
also became interested in a 
large family of immune cell receptors, 
known as the Toll family, that allows the 
host to distinguish between various types 
of pathogens (4, 5).
Now, as cofounder and director of 
the Institute for Systems Biology (ISB) 
in Seattle, WA, Aderem deals with the 
immense. His researchers collect vast 
amounts of data on a daily basis. He now 
spends his days organizing and analyzing 
this enormous load.
MELDING WORLDS
I’ve heard you had a history of political 
involvement as a young man in 
South Africa.
I was very active in the anti-Apartheid 
movement and the African National 
Congress. I had an active role in the 
trade unions and community movements 
and edited a township newspaper. I 
ended up under house arrest for fi  ve 
years and in prison.
Wow. So how did you go from activist to 
immunologist?
When I left South Africa in 1980, I tried 
to pull together my two lives: science 
and the politics of the developing world. 
The only way I could see doing that was 
to work on infectious diseases that 
mattered to people in resource-poor 
countries, like malaria and TB.
So I went to the Rockefeller Univer-
sity and worked with Zan Cohn, who 
was the macrophage maven. He con-
vinced me that infections come and go, 
but the host remains. He said I should 
work on the host response to infections 
rather than focus on any one pathogen. 
That was the best advice I ever had. For 
example, when HIV came along later, 
I was well positioned for that.
Zan was a remarkable person and an 
incredible mentor. At the time, it was 
a fantastic lab: Ralph Steinman, Gilla 
Kaplan, Sam Silverstein, Ira Mellman, 
Carl Nathan, Dan Portnoy, and others.
How did you become involved in systems 
biology?
In ’94, I started wondering what was 
going to happen when the genome was 
sequenced and how that information 
could be best used. At that time, I ran 
into Lee Hood, who was having simi-
lar thoughts. We came to the same 
conclusion—that the way to go would 
be to combine biology, technology, and 
computation. I was eager then to move 
to Seattle, where Lee had also just moved, 
so we could set up an institute that might 
do this. Together with Ruedi Aebersold, 
we cofounded the ISB in 2000.
What was so appealing about Seattle?
I was initially moving to the immunology 
department at the University of Wash-
ington, and they had some really good 
immunologists there that I wanted to 
interact with, including Sasha Rudensky, 
Mike Bevan, and Roger Perlmutter.
Seattle was also great because of its 
computational infrastructures. You had 
Microsoft and lots of young people around. 
They’d changed the world once, and they 
believed they could change it again.
Finally, I’m a serious sailor. I come 
from Capetown, where you have moun-
tains and sea, and I wanted to get back 
to that at some level. They say when 
sailors die and go to heaven, they go to 
the Pacific Northwest.
So you’re already dead?
Yes, but rigor mortis hasn’t set in.
Your original plan was to establish the 
institute at the University of Washington?
Yes, but for structural reasons we couldn’t 
do it there. We needed a lot of freedom to 
move, without the walls of departments. 
To do proper systems biology, you need 
teamwork. You need to have people with 
complementary skills working together 
under one roof: from hardcore mathema-
ticians, physicists, chemists, biologists, 
physicians, epidemiologists, ecologists, etc. 
And teamwork’s basically the kiss of death 
for an academic career. They’ll always say, 
“What did she do?” Not, “What did she 
do with fi  ve colleagues?”
We also needed global technologies—
robots and very big, very expensive 
machines, the kind of stuff that you can 
normally get in a company but not in a 
university. Within particular departments, 
you might have one mass spectrometer. 
But we need more than that.
And we needed to establish relation-
ships with companies. For example, our 
engineers might build a prototype of an 
instrument, but to actually build a robust 
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instrument, you need to interface with 
companies. Those sorts of things are 
extremely difficult to do in a university.
A SYSTEMS APPROACH
How would you defi  ne “systems biology”?
My defi  nition is a comprehensive, quanti-
tative analysis of the manner in which all 
the components of a biological system 
interact functionally and over time.
The underlying principle is that the 
question comes from biology. And if it 
can’t be answered by the technology 
that’s available at the time, then the 
technology is developed. That technol-
ogy can then revolutionize biology in 
general. For example, Lee’s motivation 
for developing the DNA sequencer was 
to answer a question regarding antibody 
structure. But once it was built, it en-
abled the genome to be sequenced. 
Biology drives technology, and then 
technology revolutionizes biology.
The most important aspect of systems-
level analysis is that you have a shot at 
understanding emergence. Complex 
systems are not demonstrated by the 
individual parts, so they can’t be predicted 
even if you completely understand the 
parts alone. Life is like that. It’s not inher-
ent in DNA and RNA and protein and 
carbohydrate and lipid. You can take all 
of those things and mix them in a bowl, 
and you don’t have life. Life’s a conse-
quence of their actions and interactions.
To identify the emergent properties 
of a biological system, you’ve got to cap-
ture an enormous amount of information 
about it, and you need to be able to infer 
its emergent properties computationally.
Is immunology particularly well-suited for 
systems analysis?
I think so, yes. First, it is a system. And you 
can isolate the cells in a functional state. 
This allows you to perturb and interrogate 
them. Once you have the right tools in 
hand you can extend your investigation in 
vivo. You can’t easily do that with organs. 
It is very hard to tease the brain apart and 
get diff  erent types of cells that will com-
municate with each other in a dish.
What are the institute's long-term goals?
I think the real societal benefi  t of sys-
tems biology is going to be predictive, 
preventive, and personalized medicine.
Cure is more likely for most diseases if 
they are identified early. The predictive 
component comes from two ends. One is 
your genes: polymorphisms and mutations 
that predispose you to various diseases. 
The other is biomarkers that define your 
particular health status at a given time. 
Biomarkers must be multi-parameter, for 
example, the proteome of the blood or the 
transcriptional profile of a circulating cell.
The preventive side would be inter-
vening by changing your diet or your 
habits, or taking a drug or vaccine.
The personalized aspect would be 
tailoring the therapy to the needs of the 
individual. If you integrate someone’s 
genetic information with their health 
status, you can individualize the therapy.
And we’ve thrown in one additional 
component, which we call the fourth P, 
for participatory. If you had access to 
medical information and all your data, 
you could very much be involved in 
shaping your treatment and your health.
Do you fear any ethical issues associated 
with access to that sort of information?
Yes, in the sense that insurance compa-
nies would love to get a hold of that 
information, for instance. But those 
things can be handled. People deal with 
their banks through the web; safeguards 
exist when you buy something on the 
internet; we can protect the information.
There are much more difficult ques-
tions. For example, if you have an incur-
able disease is it better to know? Is it 
worth leading a constrained life, because 
you know that at some point in the fu-
ture, you’re going to develop X disease?
LEADING THE CHARGE
What are some of the challenges you’ve 
encountered as institute director?
One diffi   culty has been to get scientifi  c 
integration among the various disciplines. 
I had initially thought that the physicists 
would understand biology rather easily, 
because they’d all splashed around in 
rock pools and things like that as kids, 
but that the biologists 
would have a terrible 
time with the mathe-
matics of physics.
But it turned out to 
be exactly the opposite. 
Because biologists are 
trained quantitatively, 
they can sit down and 
figure out how to pro-
gram a computer or do the quantitative 
sciences. But the physicists strive for 
simplicity, one equation that describes it 
all. The complication of biology, they 
hate it. The reason for that, of course, is 
evolution. Evolution is whatever works; 
there’s often no logic in the design. You 
can’t easily reverse-engineer something 
that’s evolved.
Having been politically involved yourself, do 
you recommend the same for other scientists?
Absolutely! Serious assaults are being 
made on science. More than half of the 
country doesn’t believe in evolution. 
Scientists need to get out there and 
educate people; for people to practice 
democracy, they need to understand the 
issues. You can’t vote on stem cells if you 
don’t know what a stem cell is. It’s all 
very well to sit in our ivory towers and 
say, “It’s not our business.” But actually it 
very much is our business.
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